Mammaglobin as a Marker for the Detection of Tumor Cells in the Peripheral Blood of Breast Cancer Patients

O. Zach,H. Kasparu,H. Wagner,O. Krieger,D. Lutz
DOI: https://doi.org/10.1111/j.1749-6632.2000.tb05547.x
IF: 6.499
2000-12-01
Annals of the New York Academy of Sciences
Abstract:The detection of circulating tumor cells in the peripheral blood (pB) of breast cancer (BC) patients might become an important factor for the prognosis of BC patients. Sensitive molecular techniques, primarily based upon the reverse-transcriptase polymerase chain reaction (RT-PCR), have been developed using the expression of tissueand/or tumor-specific genes as a marker for the presence of tumor cells. In 1996, the cDNA of a novel gene termed human mammaglobin (hMAM) was described.1 As far as known, the expression of hMAM is restricted to the adult mammary gland and to breast carcinoma cells; therefore, it might be a specific marker for BC cells. We developed a nested RT-PCR assay for the detection of hMAM mRNA molecules in the pB of BC patients as a marker for the presence of tumor cells.2 The assay is highly sensitive (1 tumor cell detectable in 106–107 white blood cells) and specific for breast carcinoma cells (no hMAM expression in pB of healthy volunteers). Peripheral blood samples from 286 BC patients (27–94 years, mean of 58 years) were classified into four defined clinical subgroups: before (pre) and after (post) surgery (without metastases and before any further adjuvant treatment), no evidence of disease (NED, stages I–III or relapsed, and after chemotherapy-induced remission), and metastatic disease (MD, stage IV and relapses of earlier stages). RNA was isolated out of 2× 5 mL pB per sample and patient, cDNA was synthesized, and nested PCR was performed with two PCR setups per cDNA, resulting in four PCR setups per sample.2 In all assays, freshly prepared cDNAs from dilutions of 10 cells of the mammary carcinoma cell line SKBR5 in 5 mL pB and from pB of healthy volunteers were used as positive and negative controls, respectively. Results of pB samples from BC patients tested for hMAM mRNA expression via a nested RT-PCR assay were as follows: 2/46 (4%) pre, 2/24 (8%) post, 4/135 (3%) NED, and 35/81 (43%) MD (TABLE 1). Significantly more MD patients were hMAM-positive than patients of the other subgroups (p < 0.0001). The detection of tumor cells in pB of BC patients is limited to tumors that do express hMAM. It has been shown that about 80% of mammary carcinomas are strongly immunopositive for hMAM protein.3 In addition, cells derived from breast
What problem does this paper attempt to address?